[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:mecom-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"MECOM Gene",5,4,[8,16,23,30,36],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07059975","UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML",[12],"Early Phase 1","RECRUITING","2026-08-26T02:17:22.949982Z","2026-05-05T02:43:29.190474Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06158828","Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:22.309547Z","2026-05-05T02:43:28.284461Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06152809","CIML NK Cells With Venetoclax for AML",[27],"Phase 1","2026-08-26T02:15:47.754948Z","2026-05-05T02:43:28.162326Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07508982","Phase1b\u002F2 Trial Of AZA + APG1252 In Patients With High-Risk AML",[20],"2026-08-26T02:19:01.741747Z","2026-05-05T02:43:27.099731Z",{"nct_id":37,"title":38,"phases":39,"status":41,"updated_at":42,"content_modified":43},"NCT07634536","Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant",[40],"Phase 2","NOT_YET_RECRUITING","2026-08-26T02:16:51.982021Z","2026-06-14T18:39:22.254845Z"]